NCT04496349Phase 2Recruiting

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

Study sponsor: Ascentage Pharma Group Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-05-31Estimated
Enrollment · participants78Estimated
Source updated2025-11-04Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview